Alnylam Pharmaceuticals
Alnylam
Alnylam Pharmaceuticals is a prominent RNAi therapeutics company that was incubated by ARCH Capital . In the view of BlueRun Ventures, it is best known as "the famous small-nucleic-acid drug company" that has begun expanding into peptide-oligonucleotide conjugate (POC) drug delivery systems . As of late 2024, Alnylam was co-developing a POC platform with PeptiDream, part of a broader shift toward using innovative peptide molecules to achieve tissue- and cell-selective delivery of oligonucleotides, with applications in oncology and metabolic diseases . The company is also cited alongside Ionis as an industry leader that has built its own POC platform .
AI-generated — may contain errors, please verify.
Coverage
On the Eve of IPO, a Conversation with METiS Pharmaceuticals' Caida Lai: From Formulas on a Whiteboard to "The SpaceX of Pharma"
The story behind the investment.
Metis Pharmaceuticals lists today, marking Monolith's first HKEX IPO
The scientist who pitched in a KFC just went public today.
AI for Science Investment and Entrepreneurship: Where Are the Opportunities in the Next Decade?
"That failed data is valuable."
Venture Studio: When Investors Become Startup Producers | He Lan on Entrepreneurship
Step Forward, Step Inside
Li Feng: One Chart to Decode Biotech Innovation Opportunities | Your Complete Guide to the FreeS Fund 2020 Biomedical Summit
Three Livestreams and One Offline Symposium, Decoding the Era of Biomedical Innovation
